This makes niraparib the third poly ADP-ribose polymerase (PARP) inhibitor to be approved since December 2014. The 553 patients enrolled in NOVA had been diagnosed with recurrent epithelial ovarian, ...
Niraparib continued to show a benefit over placebo for patients with ovarian cancer regardless of HRD or gBRCA status. In the cohort of patients with non- gBRCA mutations who were either HRD-positive ...
Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...
Individualized starting dose (ISD) of niraparib reduces severe hematologic adverse events (AEs) compared to fixed starting dose in ovarian cancer patients. Implementing ISD lowers hematologic AE ...
The appraisal committee considered evidence submitted by GSK, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full details ...
Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — The addition of niraparib to abiraterone acetate and prednisone improved outcomes for certain ...
An interim analysis of the key secondary endpoint showed a median OS of 46.3 months for patients receiving niraparib versus 43.4 months for patients receiving placebo (HR 0.82, 95% CI 0.56-1.20) in ...
Patient-level data (database lock: June 20, 2016) from ENGOT-OV16/NOVA were used to derive Kaplan-Meier PFS curves for niraparib and RS for the gBRCAmut and non-gBRCAmut cohorts. The time horizon for ...
LOUISVILLE, Ky--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by The Janssen Pharmaceutical Companies of Johnson & Johnson ...
Tesaro’s niraparib has been approved as a maintenance therapy for ovarian cancer in the US, although the company experienced a setback in its bid to develop the drug in breast cancer after patients ...
The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results